A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes
Key facts
- Who runs it
- Takeda
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- 1 Oct 2021
- Ended
- 8 Nov 2024
- Type of study
- Interventional
- Treatments tested
- Pevonedistat
- Decitabine
- Cedazuridine
- Record updated
- 29 September 2021
- Why it stopped
- Sponsor Decision to Terminate Trial
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Documented morphologically confirmed diagnosis of HR MDS according to the 2016 World Health Organisation (WHO) classification
- All participants must also have one of the following Prognostic Risk Categories based on the Revised International Prognostic Staging System (IPSS-R): Very high >6 points, high (4.5 to 6 points), or intermediate >3 to 4.5 points. Participants in the intermediate category must have >5% bone marrow myeloblasts
- Have an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of ≤2
- Able to undergo the study-required bone marrow sample collection procedures
- Suitable venous access for the study-required blood sampling (i.e., including pharmacokinetic (PK) sampling)
- Known Human Immunodeficiency Virus (HIV)-positive participants who meet the following criteria will be considered eligible:; Cluster of differentiation 4 (CD4) count >350 cells per cubic millimeter (cells/mm\^3); Undetectable viral load; Maintained on modern therapeutic regimens; No history of Acquired Immune Deficiency Syndrome (AIDS)-defining opportunistic infections
Who cannot take part
- Previous treatment for HR MDS with chemotherapy or other antineoplastic agents, including hypomethylating agents (HMAs), such as decitabine or azacitidine. Previous treatment is permitted with hydroxyurea and with lenalidomide, except that lenalidomide may not be given within 8 weeks before the first dose of study drug(s)
- Diagnosed or treated for another malignancy within 2 years before enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone resection
- Are known hepatitis B surface antigen seropositive, or known or suspected active hepatitis C infection. (Note: Participants who have isolated positive hepatitis B core antibody [i.e., in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody] must have an undetectable hepatitis B viral load. Participants with history of hepatitis C virus [HCV] infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.)
- Have known cardiopulmonary disease, defined as unstable angina, clinically significant arrhythmia, congestive heart failure (New York Heart Association Class III or IV), and/or myocardial infarction within 6 months before first dose, or severe pulmonary hypertension. As an example, well-controlled atrial fibrillation (AF) would not be an exclusion, whereas uncontrolled AF would be an exclusion
- Participants who have had a known infection of SARS-CoV-2 or COVID-19 are permitted if COVID-19 RT-PCR test is negative prior to the screening visit and they present with no symptoms. Participants with documented vaccination history for COVID-19 do not need to be tested, unless they are symptomatic, according to institutional policy and/or local regulatory guidelines
- Have known hypersensitivity to pevonedistat or its excipients
- Have known hypersensitivity to oral decitabine and cedazuridine or its excipients
- Participants with either clinical evidence of or history of central nervous system (CNS) involvement
- Have known hepatic cirrhosis or severe pre-existing hepatic impairment
- Have positive test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that is laboratory confirmed by a reverse transcription polymerase chain reaction (RT-PCR) test at screening. Testing related to coronavirus disease 2019 (COVID-19) must be performed according to institutional policy and/or per local regulatory guidelines
- Histologically or cytologically documented diagnosis of Acute Myelogenous Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)
About the trial
What the trial wants to find out
The main aim of the study is to see if signs and symptoms of myelodysplastic syndromes disappear when treated with pevonedistat combined with decitabine and cedazuridine.
Read full original descriptionShow less
Participants will receive an infusion of pevonedistat 3 times during a 28-day cycle. They will also take decitabine and cedazuridine tablets once a day for the first 5 days of the same cycle. A minimum of 6 28-day cycles is recommended, but participants can stop treatment at any time.
A bone marrow biopsy, bone marrow aspirates, and blood samples will be collected during the study.
Participants will attend a follow-up visit 30 days after their last dose of pevonedistat. Once treatment has ended, participants will be followed up with either monthly clinic visits or will be contacted every 3 months.
The group in the trial
- Pevonedistat 20 mg/m^2 + Decitabine 35 mg + Cedazuridine 100 mgTreatment being tested
Pevonedistat 20 mg/m\^2, 60-minute intravenous (IV) infusion, once daily, on Days 1, 3, and 5 in each 28-day cycle in combination with decitabine 35 mg and cedazuridine 100 mg tablets, orally, once daily on Days 1 through 5 in each 28-day cycle up to 30 months.
Treatment: Pevonedistat, Decitabine, and Cedazuridine
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2, Open-Label Study of Intravenous Pevonedistat in Combination With Oral Decitabine and Cedazuridine in Adult Patients With Higher-Risk Myelodysplastic Syndromes
- Record updated
- 29 September 2021